The Latest Breaking News from Merck

The Dow Jones Industrial Average sold off 350 points Tuesday ahead of the Federal Reserve's two-day policy meeting.

Dow Jones futures dropped after Monday's stock market rally ahead of the Federal Reserve's two-day policy meeting.

A gamble could pay off for Merck stock after blockbuster Keytruda nearly doubled the five-year survival rate for some lung cancer patients.

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

The Dow Jones moved higher into the close while blue chip stocks gained in heavy volume. Defensive sectors led the upside on Thursday.

Merck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a report Friday that sent SGEN stock tumbling.

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…